Skip to content

Ekso Bionics Holdings, Inc. (EKSO) Company Overview

Company Analysis

Ekso Bionics Holdings, Inc. EKSO

A comprehensive view of key metrics, scores, and financial health for Ekso Bionics Holdings, Inc.

Overview of Ekso Bionics Holdings, Inc.

EKSO NCM
Healthcare Medical Instruments & Supplies Micro Cap
Ekso Bionics Holdings, Inc. (EKSO), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $11.56, about 83.8% overvalued vs fair value, +78.8% 1Y return, ranked 1075/1110 in sector.
$11.56
-2.12%
As of March 13, 2026
Previous close • Vol 90d: 146.9%
52-Week Range
Market Cap
$41.19M
Enterprise Value
$42.66M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Ekso Bionics Holdings, Inc..

Top Beats
No strong beats yet

Quick Facts

HQ San Rafael, CA
Employees 50
Fiscal year Dec 31

Next Events

Earnings May 4 Estimated

Fair Value Snapshot

Bear Base Bull
$1
$2
$3
Current: $11.56 -84% vs base

Engine Room Money Flow™

Micro Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$12.8M
-28.6%%
Gross Profit
$6.8M
-28%%
Operating Income
$-13.3M
-27.4%%
Net Income
$-11.7M
-3.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
84.5%
Good

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Ekso Bionics Holdings, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
28
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
30
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing EKSO's balance between Growth (39.2%), Profitability (24.5%), and Safety (36.3%). Growth 39% Safety 36% Profitability 24%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

36th percentile vs peers
36
Key Signals
EPS Growth YoY 48.7% 75p Revenue CAGR 3Y -0.3% 36p Rev Growth YoY -28.6% 9p

No notable strengths identified for this axis.

  • Rev Growth Yoy in bottom 20% of peers (-28.6%)

Profitability

22th percentile vs peers
22
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

33th percentile vs peers
33
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Ekso Bionics Holdings, Inc..

Loading scenario defaults...
Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$1.87
- - -
-83.8% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info